Published in:
01-07-2021 | COVID-19 | Letter to the Editor
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
Authors:
Chia Siang Kow, Syed Shahzad Hasan
Published in:
Journal of Thrombosis and Thrombolysis
|
Issue 1/2021
Login to get access
Excerpt
Globally, there have been close to 130 million reported cases of coronavirus disease 2019 (COVID-19) as of 2nd April 2021, with 2.8 million deaths documented [
1]. In order to reduce the risk of mortality associated with COVID-19, several drugs have been repurposed for its treatment. However, a drug with widespread availability around the globe is particularly desirable to be repurposed for the treatment of COVID-19, since it could be immediately trialed in large-scale studies, and immediate access could be guaranteed shall the drug is proven effective to reduce the risk of COVID-19 associated deaths. One of the first drugs to be introduced for routine usage in the medical field - aspirin (also known as acetylsalicylic acid), is still one of the most widely used medications, with an estimated 50–120 billion pills consumed each year [
2]. In addition, it is one of the most researched drugs in the world, with an estimated 700–1000 clinical trials conducted annually [
3]. …
